Asston Pharmaceuticals Limited
About Asston Pharmaceuticals Limited
Data last updated: 11 March 2026
Asston Pharmaceuticals Limited is a public limited company based in Thane, Maharashtra, India. It specialises in pharmaceutical retail and distribution, a part of the broader pharmaceuticals sector. Incorporated on 16 April 2019, the company has been in operation for over 7 years.
Registered with ROC Mumbai under CIN U24304MH2019PLC324187.
Capital: an authorised share capital of ₹11 Cr and a paid-up capital of ₹8.51 Cr. It is led by directors including Sachin Chandrakant Badakh and Saili Jayaram More.
Last AGM: 29 September 2025. Financial statements filed for year ended 31 March 2025. Office: Thane, Maharashtra.
As per the financials filed for FY 2025, the company reported a revenue of ₹25.61 Cr, a growth of 57% compared to the previous year.
As per MCA filings, the company has open charges of ₹3.38 Cr and satisfied charges of ₹4.48 Cr on record.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website**************
-
Social Media**************
-
Registered Address4Th Floor Office No A – 431 Balaji Bhavan, Plot No 42A Sector – 11 Cbd Belapur Navi Mumbai, Thane, Maharashtra, India – 400614
-
IndustryPharma, Pharmaceutical Retailers & Distributors
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Asston Pharmaceuticals Limited
Asston Pharmaceuticals Limited has one previous CIN (Corporate Identification Number): U24304MH2019PTC324187. The current CIN is U24304MH2019PLC324187, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24304MH2019PLC324187 | Current |
| U24304MH2019PTC324187 | Previous |
Business Activity of Asston Pharmaceuticals Limited
Asston Pharmaceuticals Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of Asston Pharmaceuticals Limited
Asston Pharmaceuticals Limited is audited by Doshi Doshi & Co for the financial year 2025. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| Doshi Doshi & Co | blur-value | blur-value | blur-value |
Board of Directors of Asston Pharmaceuticals Limited
Asston Pharmaceuticals Limited is currently managed by 8 directors, with 4 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Sachin Chandrakant Badakh
Also directs:
Asston Pharmaceuticals Limited, Ferron Lifecare Private Limited
|
Director | 17 May 2024 | 2 Years 1 Months | Current |
|
Saili Jayaram More
Also directs:
Asston Pharmaceuticals Limited
|
Whole-Time Director | 16 Apr 2019 | 7 Years 2 Months | Current |
| Vijaya E Shahapurkar | Director | 20 Sep 2024 | 1 Years 9 Months | Current |
| Rishabh Kumar Jain | Director | 20 Sep 2024 | 1 Years 9 Months | Current |
|
Ashish Narayan Sakalkar
Also directs:
Asston Pharmaceuticals Limited, Ferron Lifecare Private Limited
|
Managing Director | 16 Apr 2019 | 7 Years 2 Months | Current |
|
Yogesh Prakash Supekar
Also directs:
Asston Pharmaceuticals Limited
|
Additional Director | 16 Oct 2025 | 0 Years 8 Months | Current |
Financials of Asston Pharmaceuticals Limited FY 2025 filings available
Asston Pharmaceuticals Limited reported revenue of ₹25.61 Cr (up 57% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Asston Pharmaceuticals Limited
As of FY 2025, Asston Pharmaceuticals Limited's shareholding pattern shows 69.07% by promoters, 29.43% by public shareholders, 1.50% by others. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Charges & Borrowings of Asston Pharmaceuticals Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 27 Jan 2026 | Hdfc Bank Limited | ₹18 Lakh | Open |
| 23 Jan 2026 | Hdfc Bank Limited | ₹23.7 Lakh | Open |
| 16 Jan 2026 | Hdfc Bank Limited | ₹24 Lakh | Open |
| 09 Jan 2026 | Hdfc Bank Limited | ₹24 Lakh | Open |
| 30 Oct 2025 | Hdfc Bank Limited | ₹2.21 Cr | Open |
Total charge records: 10 View all charges
Employees and EPFO Compliance at Asston Pharmaceuticals Limited
View historical data on people associated with Asston Pharmaceuticals Limited, including employment history and EPFO contributions.
Employee Count & EPFO Data of Asston Pharmaceuticals Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Asston Pharmaceuticals Limited
GSTIN & GST Filing Data of Asston Pharmaceuticals Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Asston Pharmaceuticals Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Asston Pharmaceuticals Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Asston Pharmaceuticals Limited
MSME Payment Delays by Asston Pharmaceuticals Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Asston Pharmaceuticals Limited
Subsidiaries & Group Companies of Asston Pharmaceuticals Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Asston Pharmaceuticals Limited with ownership details.
MCA Filings & Documents of Asston Pharmaceuticals Limited
MCA Filings & Documents of Asston Pharmaceuticals Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Asston Pharmaceuticals Limited
Frequently Asked Questions about Asston Pharmaceuticals Limited
Asston Pharmaceuticals Limited is an active public limited company in the pharma sector based in Thane, Maharashtra, India. It was incorporated on 16 April 2019 (7+ years old) and is registered under CIN U24304MH2019PLC324187.
Asston Pharmaceuticals Limited reported revenue of ₹25.61 Cr for FY 2025 (up 57.00% YoY).
The current directors of Asston Pharmaceuticals Limited are:
- Sachin Chandrakant Badakh
- Saili Jayaram More
- Vijaya E Shahapurkar
- Rishabh Kumar Jain
- Ashish Narayan Sakalkar
- Saili Jayaram More
- Yogesh Prakash Supekar
- Rishi Upadhaya
The primary industry of Asston Pharmaceuticals Limited is pharma. The company specifically operates in pharmaceutical retailers and distributors. The company is currently active in this sector.
Asston Pharmaceuticals Limited can be reached at the registered office: 4Th Floor Office No A – 431 Balaji Bhavan, Plot No 42A Sector – 11 Cbd Belapur Navi Mumbai, Thane, Maharashtra, India – 400614.
The authorised capital is ₹11 Cr, and the paid-up capital is ₹8.51 Cr.